Day Gain | ||
Gain | ||
Market Val | ||
Costs | ||
Cash | ||
Portfolio | ||
Realized | ||
Dividend |
Madrigal Pharmaceuticals (NASDAQ:MDGL) Trading Down 6% | news.google.com • |
Madrigal: 2 Challenges To Overcome To Maintain NASH 'First Mover' Advantage (NASDAQ:MDGL) | news.google.com • |
Nisa Investment Advisors LLC Sells 90 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) | news.google.com • |
Madrigal Pharmaceuticals (NASDAQ:MDGL) Research Coverage Started at Bank of America | news.google.com • |
Objective long/short (MDGL) Report | news.google.com • |
Madrigal Pharmaceuticals Becomes Oversold (MDGL) | news.google.com • |
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-05-07 | 2024-03 | -6.06 | N/A | N/A | N/A |
2024-02-28 | 2023-12 | -5.32 | -5.68 | -0.36 | -6.77% |
2023-11-06 | 2023-09 | -4.78 | -5.34 | -0.56 | -11.72% |
2023-08-08 | 2023-06 | -4.47 | -4.69 | -0.22 | -4.92% |
2023-05-09 | 2023-03 | -4.98 | -4.23 | 0.75 | 15.06% |
2023-02-23 | 2022-12 | -4.41 | -4.98 | -0.57 | -12.93% |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-09-18 | Evercore ISI Group | Upgrade | Outperform | Outperform |
2023-09-13 | HC Wainwright & Co. | Upgrade | Buy | Buy |
2023-09-11 | HC Wainwright & Co. | Upgrade | Buy | Buy |
2023-09-10 | B. Riley Securities | Upgrade | Neutral | Neutral |
2023-09-04 | B. Riley Securities | Upgrade | Neutral | Neutral |
2023-08-08 | Oppenheimer | Upgrade | Outperform | Outperform |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2024-04-01 | BATE KENNETH M | Director | 1.20K | Sale |
2024-04-01 | DALY JAMES M. | Director | 1.20K | Sale |
2024-04-07 | FRIEDMAN PAUL A | Director | 841.28K | Sale |
2024-01-22 | HOWARTH ALEX G | Chief Financial Officer | 18.74K | Stock Award(Grant) |
2024-01-22 | HUNTSMAN CAROLE | Officer | 11.47K | Stock Award(Grant) |
2024-03-31 | LEVY RICHARD S | Director | 10.30K | Sale |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Baker Brothers Advisors, LLC | 1.55M | 356.92M | 8.36% |
2023-06-29 | Avoro Capital Advisors LLC | 1.52M | 350.00M | 8.20% |
2023-06-29 | Janus Henderson Group PLC | 1.48M | 342.83M | 8.03% |
2023-06-29 | Vanguard Group Inc | 1.47M | 338.54M | 7.93% |
2023-06-29 | Blackrock Inc. | 1.04M | 241.06M | 5.65% |
2023-06-29 | State Street Corporation | 543.76K | 125.61M | 2.94% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Total Stock Market Index Fund | 453.15K | 104.68M | 2.45% |
2023-06-29 | Vanguard Small-Cap Index Fund | 377.69K | 87.25M | 2.04% |
2023-06-29 | Janus Henderson Contrarian Fund | 324.94K | 75.06M | 1.76% |
2023-08-30 | iShares Russell 2000 ETF | 310.57K | 55.90M | 1.68% |
2023-08-30 | SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | 263.58K | 47.44M | 1.43% |
2023-06-29 | Vanguard Small Cap Value Index Fund | 261.54K | 60.42M | 1.42% |
Split | Date |
---|---|
1 : 35 | 2016-07-25 |
-
Hello everyone
-
$DIS In all my years of trading and research, the most valuable insight was getting in touch with a professional trader and analyst like Mrs Susan Peterson and getting my first profit of six figures thru her from my initial deposit of 4 figures within short period. She's indeed knows how to react to the market. Link with her on Facebook "Susan Forex Peterson" for financial freedom.
Folks let's get ready to take the kids to Disney ️. Merry Christmas in advance
-
$MDGL $DWAC $ $TSLA $DIS In all my years of trading and research, the most valuable insight was getting in touch with a professional trader and analyst like Mrs Susan Peterson and getting my first profit of six figures thru her from my initial deposit of 4 figures within short period. She's indeed knows how to react to the market. Link with her on Facebook "Susan Forex Peterson" for financial freedom.
Folks let's get ready to take the kids to Disney ️. Merry Christmas in advance
-
-
-
-
When selling puts don’t be greedy. Always be closing.
-
When selling cash secured puts Be prepared to own the shares if stock drops below strike. If trial results don’t achieve objective the underlying stock can easily drop 50%.
-
-
No, no delay
-
Madrigal Pharmaceuticals (NASDAQ:MDGL) Trading Down 6%
news.google.com • -
Objective long/short (MDGL) Report
news.google.com • -
Madrigal Pharmaceuticals Becomes Oversold (MDGL)
news.google.com • -
1 No-Brainer Growth Stock to Buy Now
fool.com • -
The 3 Best Biotech Stocks to Buy in April 2024
investorplace.com • -
2 Top Biotech Buyout Candidates
zacks.com • -
7 Biotech Stocks Ready to Ride the Sector's Resurgence
investorplace.com • -
Madrigal: Accelerated Rezdiffra Approval Puts It In The NASH Lead
seekingalpha.com • -
Biotech Stock Soars on FDA Drug Approval
schaeffersresearch.com • -
Madrigal Pharmaceuticals wins FDA approval for liver disease drug; shares soar
proactiveinvestors.com • -
MDGL Stock Alert: The Historic Reason Madrigal Is Up 19% Today
investorplace.com • -
Analysts see over 50% gains in these 2 mid-cap biotech stocks
marketbeat.com • -
3 Biotech Bull Cases To Consider In 2024 - And 2 Wildcard Recommendations
seekingalpha.com • -
Huge Warren Buffett Purchase Highlights Hot Insider Buying
247wallst.com • -
The 3 Most Undervalued Biotech Stocks to Buy: November 2023
investorplace.com • -
2 Risky Stocks With Massive Potential
fool.com • -
Madrigal Pharmaceuticals shares fall after new CEO named
marketwatch.com • -
The 3 Best Biotech Stocks to Buy Now: September 2023
investorplace.com • -
3 Biotech Stocks That Wall Street Analysts Can't Get Enough Of
investorplace.com • -
The 3 Most Promising Pharma Stocks to Own Now
investorplace.com • -
Madrigal's Resmetirom Nears Commercialization Despite Market Concerns
seekingalpha.com • -
Madrigal: With Successful NASH Study, Possible Accelerated Approval Is Next
seekingalpha.com • -
Weight-loss drugs in development aim to replace injections with pills
marketwatch.com • -
Madrigal: Setting The Pace In The NASH Market (Rating Upgrade)
seekingalpha.com • -
Why These 3 Nasdaq Stocks Buckled Today
fool.com • -
3 Biotechs That Might Get Bought Out in 2023
fool.com • -
These Are the Top 10 Holdings of Avoro Capital Advisors
247wallst.com • -
5 Best Stocks to Buy in April
fool.com • -
A Perfect Storm In Pharmacotherapy: The Opportunity To Invest In NASH
seekingalpha.com • -
5 Best and Worst Performing Mid-Cap Stocks in Q4 2022
247wallst.com • -
Madrigal: Fairly Valued At These Levels
seekingalpha.com • -
3 Top Healthcare Stocks to Buy for January
fool.com • -
Why These 7 Healthcare Stocks Could Soar in 2023
investorplace.com • -
Madrigal Pharmaceuticals Setting The Standard
seekingalpha.com • -
Madrigal Pharmaceuticals: Upcoming Windfall Profits
seekingalpha.com • -
7 Drug Stocks That Will Soar in 2023
investorplace.com • -
Madrigal: Next Steps After 'Wow' Data In NASH
seekingalpha.com • -
Madrigal's Successful Late-Stage Trial Draws Options Bulls
schaeffersresearch.com • -
Madrigal Pharmaceuticals Stock Is Up 200% In One Day, Here's Why
marketbeat.com • -
Why Is Madrigal Pharmaceuticals (MDGL) Stock Up 216% Today?
investorplace.com • -
Madrigal: Binary Catalyst Unlocking
seekingalpha.com • -
Madrigal Pharmaceuticals Forecast: Not So Clear
seekingalpha.com • -
Madrigal: Buy And Hoard Before Q4 Data Readout
seekingalpha.com • -
Trial Results Set to Make or Break Small-Cap Pharma Stocks
gurufocus.com • -
Madrigal: Clear Path Ahead
seekingalpha.com • -
Madrigal: NASH Data In Q4 Is The Key
seekingalpha.com • -
Madrigal Pharmaceuticals to Present at the Oppenheimer Healthcare Conference
globenewswire.com • -
3 Graham's Lost Formula Stocks to Consider for February
gurufocus.com • -
Madrigal NASH Data Is Promising, Next Study Is Key For Success
seekingalpha.com •